Beijing Guolian Chenghui Medicine Technology Co., Ltd.

The purpose of this study is to study the pharmacokinetics of amoxicillin and ambroxol tablets (each tablet contains 250 mg amoxicillin and 15 mg ambroxol hydrochloride) developed and produced by Beijing Guolian Chenghui Pharmaceutical Technology Co., Ltd. and a single preparation (amoxicillin tablets or ambroxol hydrochloride tablets) in healthy humans, so as to provide pharmacokinetic data on whether amoxicillin and ambroxol affect each other in healthy humans, provide clinical trial basis for whether the formulation design of the drug is reasonable, and provide basis for conducting phase II clinical research on the drug.

The purpose of this study is to study the relative bioavailability of the dry mixed suspension (each bag contains 125 mg amoxicillin and 7.5 mg ambroxol hydrochloride) and amoxicillin ambroxol capsules (each capsule contains 250 mg amoxicillin and 15 mg ambroxol hydrochloride) developed and produced by Beijing Guolian Chenghui Pharmaceutical Technology Co., Ltd. in healthy humans, and to provide a basis for whether they are bioequivalent to the amoxicillin ambroxol tablets produced by the company.

To evaluate the efficacy and safety of 2% liranapthate cream in the treatment of tinea corporis and tinea pedis by comparing it with 1% butenafine ointment